培美曲塞联合顺铂治疗晚期非小细胞肺癌的临床疗效观察.pdf

《培美曲塞联合顺铂治疗晚期非小细胞肺癌的临床疗效观察.pdf》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。

1、现代生物医学进展www~hengwuyixue．eomProgressinModernBiome~cmeVoL14N0．14MAY．2014·2719·doi：10．13241／j．cnki．pmb．2014．14．028培美曲塞联合顺铂治疗晚期非小细胞肺癌的临床疗效观察卢路定韩光明刘洪波姚瑞李毅刚(广东省韶关市粤北人民医院肿瘤科广东韶关512000)摘要目的：探讨培美曲塞联合顺铂治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法：随机选取我院肿瘤科晚期NSCLC患者177例，随机将其分为3组，培美曲塞联合顺铂治疗

2、(PP组)72例，多西他赛联合顺铂治疗(DP组)53例，吉西他滨联合顺铂治疗(GP组)52例，比较三组治疗方法的临床疗效与不良反应之间的差异，根据临床疗效将PP组分为有效组与无效组，分析培美曲塞联合顺铂治疗晚期NSCLC的影响因素。结果：PP组疾病控制率(DCR)与客观有效率(ORR)均显著高于GP组(均P<0．05)；PP组与DP组近期疗效之间的比较无显著差异(均P>0．05)。PP组的药物毒副作用均显著优于DP组与GP组(均P<0．05oPP组的中位生存期显著高于DP组与GP组(均P

3、与Ⅳ期晚期NSCLC患者中，培美曲塞联合顺铂治疗有效率更高。结论：培美曲塞治疗晚期NSCLC的疗效佳，与多西他赛相当并显著优于吉西他滨治疗，药物毒副作用小，且受吸烟状况、病理类型与临床分期影响。关键词：培美曲塞；顺铂；多西他赛；吉西他滨；临床疗效中图分类号：R734．2文献标识码：A文章编号：1673．6273(2014)14—2719．04ClinicalCurativeEffectObservationofAdvancedNon—SmallCellLungCancerTreatedbyPemetrexedCom

4、binedCisplatin工u—dhTg',HANGuang-ming,LIUHong-bo,YAORui,LIYi-gang(OncologyDepartment,ShaoguanYuebeiPeople'sHospitalofGuangdongProvince,Shaoguan,Guangdong,512000,China)ABSTRACTObjective：Tostudyclinicalcurativeefectofadvancednon-smallcelllungcancer(NSCLC)treatedb

5、yPemetrexedcombinedcisplatin．Methods：177casesofadvancedNSCLCpatientswereselectedfromOurhospitalanddividedinto3groupsrandomly,PPgroup(n=72)gavetreatmentofpemetrexedcombinedcisplatin，DPgroup(n：53)gavetreatmentofdocetaxelcombinedcisplatin，GPgroup(n=52)gavetreatme

6、ntofgemcitabinecombinedcisplatin，clinicalcurativeefectandadversereactionwerecompared．Accordingtoclinicaleficacy，PPgroupwasdividedintoefectivegroupandinefectivegroup，analyzedfactorsforthetreatmentofpemetrexedcombinedcisplatintoadvancedNSCLC．Results：DCRandORRofP

7、PgroupweresignificantlyhigherthanthatofGPgroup(allP<0．O5)；ThecomparisonbetweenPPgroupandDPgroupinthenearfuturecurativeefecthadnosignificantdiferencerP>0．05)．ThedrugsideefectofPPgroupweresignificantlysuperiortoDPgroupandGPgroup(allP<0．05)．MediansurialinPPgroupi

8、ssignificantlyhigherthanDPgroupandGPgroup(allP